Page 1394 - Williams Hematology ( PDFDrive )

1368 Part X: Malignant Myeloid Diseases Chapter 87: Myelodysplastic Syndromes 1369

400. Will B, Kawahara M, Luciano JP, et al: Effect of the nonpeptide thrombopoietin recep- 429. Aul C, Gattermann N: The role of low-dose chemotherapy in myelodysplastic syn-
tor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leuke- dromes. Leuk Res 16(3):207–215, 1992.
mia and myelodysplastic syndrome. Blood 114(18):3899–3908, 2009. 430. Miller KB, Kim K, Morrison FS, et al: The evaluation of low-dose cytarabine in the
401. Giagounidis A, Mufti GJ, Fenaux P, et al: Results of a randomized, double-blind study of treatment of myelodysplastic syndromes: A phase-III intergroup study. Ann Hematol
romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic 65(4):162–168, 1992.
syndrome and thrombocytopenia. Cancer 120(12):1838–1846, 2014. 431. Fenaux P, Gattermann N, Seymour JF, et al: Prolonged survival with improved tolera-
402. Kuter DJ, Mufti GJ, Bain BJ, et al: Evaluation of bone marrow reticulin formation bility in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose
in chronic immune thrombocytopenia patients treated with romiplostim. Blood ara-C. Br J Haematol 149(2):244–249, 2010.
114(18):3748–3756, 2009. 432. Visani G, Malagola M, Piccaluga PP, Isidori A: Low dose Ara-C for myelodysplastic
403. Steensma DP, Gattermann N: When is iron overload deleterious, and when and how syndromes: Is it still a current therapy? Leuk Lymphoma 45(8):1531–1538, 2004.
should iron chelation therapy be administered in myelodysplastic syndromes? Best 433. Sloand EM, Rezvani K: The role of the immune system in myelodysplasia: Implications
Pract Res Clin Haematol 26(4):431–444, 2013. for therapy. Semin Hematol 45(1):39–48, 2008.
404. Steensma DP: The role of iron chelation therapy for patients with myelodysplastic syn- 434. Aivado M, Rong A, Stadler M, et al: Favourable response to antithymocyte or antilym-
dromes. J Natl Compr Canc Netw 9(1):65–75, 2011. phocyte globulin in low-risk myelodysplastic syndrome patients with a “non-clonal”
405. Steensma DP: The relevance of iron overload and the appropriateness of iron chela- pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68(4):
tion therapy for patients with myelodysplastic syndromes: A dialogue and debate. Curr 210–216, 2002.
Hematol Malig Rep 6(2):136–144, 2011. 435. Selleri C, Maciejewski JP, Catalano L, et al: Effects of cyclosporine on hematopoietic
406. Leitch HA: Controversies surrounding iron chelation therapy for MDS. Blood Rev and immune functions in patients with hypoplastic myelodysplasia: In vitro and in vivo
25(1):17–31, 2011. studies. Cancer 95(9):1911–1922, 2002.
407. Goldberg SL, Chen E, Sasane M, et al: Economic impact on US Medicare of a new diag- 436. Yazji S, Giles FJ, Tsimberidou AM, et al: Antithymocyte globulin (ATG)-based therapy
nosis of myelodysplastic syndromes and the incremental costs associated with blood in patients with myelodysplastic syndromes. Leukemia 17(11):2101–2106, 2003.
transfusion need. Transfusion 52(10):2131–2138, 2012. 437. Killick SB, Mufti G, Cavenagh JD, et al: A pilot study of antithymocyte globulin (ATG)
408. Goldberg SL, Chen E, Corral M, et al: Incidence and clinical complications of mye- in the treatment of patients with “low-risk” myelodysplasia. Br J Haematol 120(4):
lodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 679–684, 2003.
28(17):2847–2852, 2010. 438. Molldrem JJ, Caples M, Mavroudis D, et al: Antithymocyte globulin for patients with
409. Leitch HA: Improving clinical outcome in patients with myelodysplastic syndrome and myelodysplastic syndrome. Br J Haematol 99(3):699–705, 1997.
iron overload using iron chelation therapy. Leuk Res 31 Suppl 3:S7–S9, 2007. 439. Kadia TM, Borthakur G, Garcia-Manero G, et al: Final results of the phase II study
410. Lyons RM, Marek BJ, Paley C, et al: Comparison of 24-month outcomes in chelated of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte
and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syn-
registry. Leuk Res 38(2):149–154, 2014. drome. Br J Haematol 157(3):312–320, 2012.
411. Rose C, Brechignac S, Vassilief D, et al: Does iron chelation therapy improve survival 440. Dixit A, Chatterjee T, Mishra P, et al: Cyclosporin A in myelodysplastic syndrome: A
in regularly transfused lower risk MDS patients? A multicenter study by the GFM preliminary report. Ann Hematol 84(9):565–568, 2005.
(Groupe Francophone des Myelodysplasies). Leuk Res 34(7):864–870, 2010. 441. Shimamoto T, Tohyama K, Okamoto T, et al: Cyclosporin A therapy for patients with
412. Neukirchen J, Fox F, Kundgen A, et al: Improved survival in MDS patients receiving myelodysplastic syndrome: Multicenter pilot studies in Japan. Leuk Res 27(9):783–788,
iron chelation therapy-a matched pair analysis of 188 patients from the Dusseldorf 2003.
MDS registry. Leuk Res 36(8):1067–1070, 2012. 442. Nozaki Y, Nagare Y, Kinoshita K, et al: Successful treatment using tacrolimus plus cor-
413. Gattermann N: Overview of guidelines on iron chelation therapy in patients with myel- ticosteroid in a patient with RA associated with MDS. Rheumatol Int 28(5):487–490,
odysplastic syndromes and transfusional iron overload. Int J Hematol 88(1):24–29, 2008. 2008.
414. Armand P, Kim HT, Cutler CS, et al: Prognostic impact of elevated pretransplantation 443. Saunthararajah Y, Nakamura R, Nam JM, et al: HLA-DR15 (DR2) is overrepresented in
serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood myelodysplastic syndrome and aplastic anemia and predicts a response to immunosup-
109(10):4586–4588, 2007. pression in myelodysplastic syndrome. Blood 100(5):1570–1574, 2002.
415. Bennett JM; MDS Foundation’s Working Group on Transfusional Iron Overload: 444. Lim ZY, Killick S, Germing U, et al: Low IPSS score and bone marrow hypocellularity
Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol in MDS patients predict hematological responses to antithymocyte globulin. Leukemia
83(11):858–861, 2008. 21(7):1436–1441, 2007.
416. Wells RA, Leber B, Buckstein R, et al: Iron overload in myelodysplastic syndromes: A 445. Wang H, Chuhjo T, Yasue S, et al: Clinical significance of a minor population of par-
Canadian consensus guideline. Leuk Res 32(9):1338–1353, 2008. oxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood
417. Di Tucci AA, Matta G, Deplano S, et al: Myocardial iron overload assessment by T2 * 100(12):3897–3902, 2002.
magnetic resonance imaging in adult transfusion dependent patients with acquired 446. Steensma DP, Dispenzieri A, Moore SB, et al: Antithymocyte globulin has limited effi-
anemias. Haematologica 93(9):1385–1388, 2008. cacy and substantial toxicity in unselected anemic patients with myelodysplastic syn-
418. List AF, Baer MR, Steensma DP, et al: Deferasirox reduces serum ferritin and labile drome. Blood 101(6):2156–2158, 2003.
plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. 447. Atoyebi W, Bywater L, Rawlings L, et al: Treatment of myelodysplasia with oral cyclo-
J Clin Oncol 30(17):2134–2139, 2012. sporin. Clin Lab Haematol 24(4):211–214, 2002.
419. Pullarkat V: Objectives of iron chelation therapy in myelodysplastic syndromes: More 448. Sloand EM, Olnes MJ, Shenoy A, et al: Alemtuzumab treatment of intermediate-1
than meets the eye? Blood 114(26):5251–5255, 2009. myelodysplasia patients is associated with sustained improvement in blood counts and
420. Cappellini MD, Porter J, El-Beshlawy A, et al: Tailoring iron chelation by iron intake cytogenetic remissions. J Clin Oncol 28(35):5166–5173, 2010.
and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with 449. Moreno-Aspitia A, Geyer S, Li C, et al: N998B: Multicenter phase II trial of thalido-
transfusion-dependent anemias. Haematologica 95(4):557–566, 2010. mide (Thal) in adult patients with myelodysplastic syndromes (MDS). Blood 100:96a,
421. Guariglia R, Martorelli MC, Villani O, et al: Positive effects on hematopoiesis in patients 2002.
with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A 450. Zorat F, Shetty V, Dutt D, et al: The clinical and biological effects of thalidomide in
brief review. Leuk Res 35(5):566–570, 2011. patients with myelodysplastic syndromes. Br J Haematol 115(4):881–894, 2001.
422. Jensen PD, Heickendorff L, Pedersen B, et al: The effect of iron chelation on haemo- 451. Ito T, Ando H, Suzuki T, et al: Identification of a primary target of thalidomide terato-
poiesis in MDS patients with transfusional iron overload. Br J Haematol 94(2):288–299, genicity. Science 327(5971):1345–1350, 2010.
1996. 452. Kronke J, Udeshi ND, Narla A, et al: Lenalidomide causes selective degradation of
423. Wisch JS, Griffin JD, Kufe DW: Response of preleukemic syndromes to continuous IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168):301–305, 2014.
infusion of low-dose cytarabine. N Engl J Med 309(26):1599–1602, 1983. 453. Lu G, Middleton RE, Sun H, et al: The myeloma drug lenalidomide promotes the cere-
424. Mufti GJ, Oscier DG, Hamblin TJ, Bell AJ: Low doses of cytarabine in the treatment blon-dependent destruction of Ikaros proteins. Science 343(6168):305–309, 2014.
of myelodysplastic syndrome and acute myeloid leukemia. N Engl J Med 309(26): 454. Zhu YX, Braggio E, Shi CX, et al: Identification of cereblon-binding proteins and
1653–1654, 1983. relationship with response and survival after IMiDs in multiple myeloma. Blood
425. Manoharan A: Low-dose cytarabine therapy in hypoplastic acute leukemia. N Engl J 124(4):536–545, 2014.
Med 309(26):1652–1653, 1983. 455. Kotla V, Goel S, Nischal S, et al: Mechanism of action of lenalidomide in hematological
426. Hellstrom-Lindberg E, Robert KH, Gahrton G, et al: A predictive model for the clinical malignancies. J Hematol Oncol 2:36, 2009.
response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or 456. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes.
acute leukaemia. Br J Haematol 81(4):503–511, 1992. N Engl J Med 352(6):549–557, 2005.
427. Ganser A, Seipelt G, Eder M, et al: Treatment of myelodysplastic syndromes with cytok- 457. Fenaux P, Giagounidis A, Selleslag D, et al: A randomized phase 3 study of lenalidomide
ines and cytotoxic drugs. Semin Oncol 19(2 Suppl 4):95–101, 1992. versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk
428. Gerhartz HH, Marcus R, Delmer A, et al: A randomized phase II study of low-dose myelodysplastic syndromes with del5q. Blood 118(14):3765–3776, 2011.
cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating fac- 458. Sekeres MA, Maciejewski JP, Giagounidis AA, et al: Relationship of treatment-related
tor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic
leukemia. EORTC Leukemia Cooperative Group. Leukemia 8(1):16–23, 1994. syndromes. J Clin Oncol 26(36):5943–5949, 2008.

Kaushansky_chapter 87_p1341-1372.indd 1369 9/21/15 11:06 AM